Estrogen metabolism-related genes and breast cancer risk: The multiethnic cohort study

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 8, 2005, Pages 1998-2003

  Le Marchand, Loïc ^a   Donlon, Timothy ^a   Kolonel, Laurence N ^a   Henderson, Brian E ^b   Wilkens, Lynne R ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; AHR GENE; ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CLINICAL STUDY; COMT GENE; CONTROLLED STUDY; CYP1A1 GENE; CYP1A2 GENE; CYP1B1 GENE; CYP3A4 GENE; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ETHNIC GROUP; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HISPANIC; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTIETHNIC COHORT STUDY; NATIVE HAWAIIAN; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SULT1A1 GENE; UNITED STATES;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; CYTOCHROME P-450 CYP1A2; ESTROGENS; ETHNIC GROUPS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; QUESTIONNAIRES;

EID: 23844551747     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0076     Document Type: Article

References (44)

1. Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder AJ, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
2. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1995;87:190-7.
3. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9.
4. Kolonel LN, Henderson BE, Hankin JH, et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 2000;151:346-57.
5. Le Marchand L, Haiman CA, Wilkens LR, Kolonel LN, Henderson BE. MTHFR polymorphisms, diet, HRT and breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2004;13:2071-7.
6. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
7. Lurie G, Maskarinec G, Kaaks R, Stanczyk F, Le Marchand L. Polymorphisms associated with serum estrogens measured multiple times during a two-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1521-7.
8. Coughtrie MWH, Gilissen RAHJ, Shek B, et al. Phenol sulphotransferase SULT1A1 polymorphism: molecular diagnosis and allele frequencies in Caucasian and African populations. Biochem J 1999;337:45-9.
9. Kawajiri K, Watanabe J, Eguchi H, et al. Polymorphisms of human Ah receptor gene are not involved in lung cancer. Pharmacogenetics 1995;5:151-8.
10. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. IARC Scientific Pub. No. 32. Lyon: IARC; 1980.
11. Nebert DW. Elevated estrogen 16α-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? J Natl Cancer Inst 1993;85:1888-91.
12. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A 1997;94:10937-42.
13. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
14. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
15. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
16. Bradlow L, Telang NT, Osborn MP. Estrogen metabolites as bioreactive modulators of tumor initiators and promoters. Adv Exp Med Biol 1996;387:285-96.
17. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci U S A 1996;93:3294-6.
18. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 1996;93:9776-81.
19. Petersen DD, McKinney CE, Ikeya K, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 1991;48:720-5.
20. Landi MT, Bertazzi PA, Shields PG, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4:242-6.
21. Mitrunen K, Hirvonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
22. Li Y, Millikan RC, Bell DA, et al. Cigarette smoking, cytochrome P4501A1 polymorphisms, and breast cancer among African-American and White women. Breast Cancer Res 2004;6:R460-73.
23. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology 2003; 144:3382-8.
24. Le Marchand L, Franke AA, Custer L, Wilkens LR, Cooney RV. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and α-tocopherol. Pharmacogenetics 1997;7:11-9.
25. Nakajima M, Yokoi T, Miutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutations prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994:3:413-21.
26. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C↓A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
27. Maskarinec G, Lurie G, Williams AE, Le Marchand L. An investigation of mammographic density and gene variants in healthy women. Int J Cancer 2004;112:683-8.
28. Pike MC, Krailo MD, Henderson BE, Casarande JT, Hoel DG. "Hormonal" risk factors, "breast tissue age" and the age-incidence of breast cancer. Nature 1983;303:767-70.
29. Zhu K, Bernard LJ, Levine RS, Williams SM. Estrogen receptor status of breast cancer: a marker of different stages of tumor or different entities of the disease? Med Hypotheses 1997;49;69-75.
30. Russo J, Russo IH. Genotoxicity of steroidal estrogens. Trends Endocrinol Met 2004;15:211-4.
31. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-13.
32. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res 1998;58:5038-41.
33. Zheng W, Xie D-W, Jin F, et al. Generic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000;9:147-50.
34. De Vivo I, Hankinson SE, Li L, Colditz GA, Hunter DJ. Association of CYP1B1 polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:489-92.
35. Swanson HI, Bradfield CA. The AH-receptor: genetics, structure and function. Pharmacogenetics 1993;3:213-30.
36. Smart J, Daly AK. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000;10:11-24.
37. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9.
38. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998;95:13176-81.
39. Spurdle AB, Goodwin B, Hodgson E, et al. The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 2002;12:355-66.
40. Kadlubar FF, Berkowitz GS, Delongchamp RR, et al. The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2003;12:327-31.
41. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-50.
42. Raftogianis RB, Wood TC, Otterness DM, Can Leon JA, Weinshilboum RM. Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 1997;239:298-304.
43. Zheng W, Xie D, Cerhan JR, Sellers TA, Wen W, Folsom AR. Sulfotransferase 1A1 polymorphism, endogenous estrogen exposure, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:89-94.
44. Tang D, Rundle A, Mooney L, et al. Sulfotransferase 1A1 (SULT1A1) polymorphism, PAH-DNA adduct levels in breast tissue and breast cancer risk in a case-control study. Breast Cancer Res Treat 2003 Mar; 78:217-22.